Allergic rhinitis: The eligible candidate to mite immunotherapy in the real world

Allergy, Asthma and Clinical Immunology

Volumn 13, Issue 1, 2017, Pages

  Ciprandi, Giorgio ^a   Natoli, Valentina ^b   Puccinelli, Paola ^b   Cristoforo, C ^c   Barberi, S ^d   Foresi, A ^d   Galli, E ^e   Gani, F ^d   Gelardi, M ^d   Lamantia, I ^f   Peroni, D ^d   Ridolo, E ^d   Senna, G E ^d   Ricciardi, L ^d   Romano, A ^e   Rossi, O ^d   Scala, G ^d   Testi, S ^d  

^a UNIVERSITY OF GENOA   (Italy)

^b Pharmacovigilance and Regulatory Department Stallergenes Greer   (Italy)

^c PARKINSON INSTITUTE   (Italy)

^d NONE   (Italy)

^e NONE   (Italy)

^f NONE   (Italy)

Author keywords

Allergen immunotherapy; Allergic rhinitis; Asthma; House dust mite allergy; Real life

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E;

ADULT; ALLERGIC RHINITIS; ASTHMA; CHILD; COUGHING; DISEASE DURATION; DYSPNEA; HOUSE DUST ALLERGY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LETTER; MAJOR CLINICAL STUDY; MALE; NOSE POLYP; PERIODICITY; PRESCRIPTION; RURAL AREA; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; VISUAL ANALOG SCALE;

EID: 85014409860     PISSN: 17101484     EISSN: 17101492     Source Type: Journal    
DOI: 10.1186/s13223-017-0185-x     Document Type: Letter

References (10)

1. Bernstein DI, Schwartz G, Bernstein JA. Allergic rhinitis: mechanisms and treatment. Immunol Allergy Clin North Am. 2016;36(2):261-78.
2. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008;63(Suppl. 86):8-160.
3. Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? J Allergy Clin Immunol. 2016;137(2):339-49.
4. Calderon MA, Casale TB, Nelson HS, Demoly P. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. J Allergy Clin Immunol. 2013;132(6):1322-36.
5. Ciprandi G, Incorvaia C, Masieri S, Buttafava S, Frati F. The best allergen immunotherapy choice for mite allergic patients. Expert Rev Clin Immunol. 2016;12(6):603-4.
6. Karaman S, Can D, Erdem SB, Nacaroglu HT, Karkiner CS, Gunay I. Is there any parameter helpful for predicting a suitable candidate for mite immunotherapy? Iran J Allergy Asthma Immunol. 2016;15(2):105-11.
7. Platts-Mills TA, Hayden ML, Chapman MD, Wilkins SR. Seasonal variation in dust mite and grass-pollen allergens in dust from the houses of patients with asthma. J Allergy Clin Immunol. 1987;79:781-91.
8. Gelardi M, Peroni DG, Incorvaia C, Quaranta N, De Luca C, Barberi S, et al. Seasonal changes in nasal cytology in mite-allergic patients. J Inflamm Res. 2014;7:39-44.
9. Leatherman B, Skoner DP, Hadley JA, Walstein N, Blaiss MS, Dykewicz MS, Craig T, Smith N, Allen-Ramey F. The Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) survey: provider practices and beliefs about allergen immunotherapy. Int Forum Allergy Rhinol. 2014;4(10):779-88.
10. Lynch SV, Wood RA, Boushey H, Bacharier LB, Bloomberg GR, Kattan M, et al. Effects of early-life exposure to allergens and bacteria on recurrent wheeze and atopy in urban children. J Allergy Clin Immunol. 2014;134(3):593-601.